Bioventus Inc. (NYSE:BVS) Stake Boosted by AlphaQuest LLC

AlphaQuest LLC increased its stake in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 810.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 38,764 shares of the company's stock after acquiring an additional 34,505 shares during the period. AlphaQuest LLC's holdings in Bioventus were worth $407,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. acquired a new position in shares of Bioventus during the third quarter worth $210,000. Covestor Ltd purchased a new stake in Bioventus during the 3rd quarter worth $69,000. Los Angeles Capital Management LLC acquired a new position in Bioventus in the 3rd quarter worth $1,714,000. GSA Capital Partners LLP boosted its position in Bioventus by 85.6% in the 3rd quarter. GSA Capital Partners LLP now owns 58,832 shares of the company's stock valued at $703,000 after buying an additional 27,132 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of Bioventus during the third quarter valued at about $385,000. Hedge funds and other institutional investors own 62.94% of the company's stock.

Insider Activity

In other news, CFO Mark Leonard Singleton sold 10,733 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total value of $113,018.49. Following the completion of the sale, the chief financial officer now directly owns 105,162 shares in the company, valued at approximately $1,107,355.86. The trade was a 9.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert E. Claypoole sold 28,786 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares in the company, valued at approximately $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,932 shares of company stock worth $512,511. 32.90% of the stock is currently owned by corporate insiders.

Remove Ads

Bioventus Stock Up 2.0 %

NYSE BVS traded up $0.19 during trading hours on Monday, reaching $9.80. 394,469 shares of the company traded hands, compared to its average volume of 422,590. The stock has a market capitalization of $795.32 million, a PE ratio of -16.07 and a beta of 0.86. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12 month low of $3.90 and a 12 month high of $14.38. The company has a 50 day moving average of $10.08 and a two-hundred day moving average of $11.02.

Wall Street Analyst Weigh In

BVS has been the topic of several recent analyst reports. JPMorgan Chase & Co. upgraded Bioventus from an "underweight" rating to a "neutral" rating and boosted their price target for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th. Canaccord Genuity Group restated a "buy" rating and set a $15.00 price objective on shares of Bioventus in a report on Monday.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.